Summit Pharmaceuticals International Corporation, a subsidiary of Sumitomo Corporation, serves as the exclusive agent for ERS Genomics in Japan
ERS Genomics has announced the signing of a license agreement with Otsuka Pharmaceutical. The license grants Otsuka access to CRISPR/Cas9 genome editing technology for its internal research and development initiatives to address areas of unmet medical need.
ERS Genomics holds an exclusive worldwide license from co-founder and recent Nobel prize winner Dr Emmannuelle Charpentier to the foundational intellectual property covering CRISPR/Cas9 for use as a research platform.
Eric Rhodes, CEO of ERS Genomics, said: “We are extremely pleased to be able to provide Otsuka with access to the CRISPR/Cas9 license. We hope this brings significant value to Otsuka as it applies the technology to its internal programs.”
ERS Genomics licensed the technology to ZeClinics in February.